Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia

Leukemia

Volumn 23, Issue 10, 2009, Pages 1771-1778

  Giannopoulos, K ^a,b   Dmoszynska, A ^a   Kowal, M ^a   Wasik Szczepanek, E ^a   Bojarska Junak, A ^a   Rolinski, J ^a   Dohner H ^b   Stilgenbauer, S ^b   Bullinger, L ^b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUDARABINE; IMMUNOGLOBULIN HEAVY CHAIN; THALIDOMIDE; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOLOGICAL ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CD3+ T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CELL COUNT; CHROMOSOME ABERRATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE EXPRESSION PROFILING; HIGH RISK PATIENT; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VIVO STUDY; LEUKEMIA CELL; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TREATMENT RESPONSE;

EID: 70350123882     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2009.98     Document Type: Article

References (34)

1. Keating MJ, Chiorazzi N, Messmer B, Damle RN, Allen SL, Rai KR et al Biology and treatment of chronic lymphocytic leukemia. Hematology (Am Soc Hematol Educ Program) 2003, 153-175.
2. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916.
3. Krober A, Seiler T, Benner A, Bullinger L, Bruckle E, Lichter P et al V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002; 100 1410-1416.
4. Montserrat E. New prognostic markers in CLL. Hematology (Am Soc Hematol Educ Program) 2006, 279-284.
5. Zenz T, Dohner H, Stilgenbauer S. Genetics and risk-stratified approach to therapy in chronic lymphocytic leukemia. Best Pract Res Clin Haematol 2007; 20: 439-453.
6. Haiat S, Billard C, Quiney C, Ajchenbaum-Cymbalista F, Kolb JP. Role of BAFF and APRIL in human B-cell chronic lymphocytic leukaemia. Immunology 2006; 118: 281-292.
7. Letilovic T, Vrhovac R, Verstovsek S, Jaksic B, Ferrajoli A. Role of angiogenesis in chronic lymphocytic leukemia. Cancer 2006; 107 925-934.
8. Nishio M, Endo T, Tsukada N, Ohata J, Kitada S, Reed JC et al. Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha. Blood 2005; 106: 1012-1020.
9. Redondo-Munoz J, Escobar-Diaz E, Samaniego R, Terol MJ, Garcia-Marco JA, Garcia-Pardo A. MMP-9 in B-cell chronic lymphocytic leukemia is up-regulated by alpha4beta1 integrin or CXCR4 engagement via distinct signaling pathways, localizes to podosomes, and is involved in cell invasion and migration. Blood 2006; 108: 3143-3151.
10. Chanan-Khan A, Porter CW. Immunomodulating drugs for chronic lymphocytic leukaemia. Lancet Oncol 2006; 7: 480-488.
11. Chanan-Khan A, Miller KC, Takeshita K, Koryzna A, Donohue K, Bernstein ZP et al. Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL). Blood 2005; 106: 3348-3352.
12. Beyer M, Kochanek M, Darabi K, Popov A, Jensen M, Endl E et al. Reduced frequencies and suppressive function of CD4+ CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005; 106: 2018-2025.
13. Giannopoulos K, Schmitt M, Kowal M, Wlasiuk P, Bojarska-Junak A, Chen J et al. Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia (B-CLL). Oncol Rep 2008; 20 677-682.
14. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446-5456.
15. Krober A, Bloehdorn J, Hafner S, Buhler A, Seiler T, Kienle D et al Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J Clin Oncol 2006; 24: 969-975.
16. Giannopoulos K, Schmitt M, Wlasiuk P, Chen J, Bojarska-Junak A, Kowal M et al. The high frequency of T regulatory cells in patients with B-cell chronic lymphocytic leukemia is diminished through treatment with thalidomide. Leukemia 2008; 22: 222-224.
17. Bojarska-Junak A, Hus I, Szczepanek EW, Dmoszynska A, Rolinski J. Peripheral blood and bone marrow TNF and TNF receptors in early and advanced stages of B-CLL in correlation with ZAP-70 protein and CD38 antigen. Leuk Res 2008; 32: 225-233.
18. Bullinger L, Rucker FG, Kurz S, Du J, Scholl C, Sander S et al. Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia. Blood 2007; 110: 1291-1300.
19. Sander S, Bullinger L, Klapproth K, Fiedler K, Kestler HA, Barth TF et al. MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood 2008; 112: 4202-4212.
20. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ et al. The Connectivity Map: Using gene-expression signatures to connect small molecules, genes, and disease. Science 2006; 313: 1929-1935.
21. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P et al Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-1571.
22. Ferrajoli A, Lee BN, Schlette EJ, O'Brien SM, Gao H, Wen S et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008; 111: 5291-5297.
23. Chanan-Khan AA, Cheson BD. Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol 2008; 26: 1544-1552.
24. Dmoszynska A, Bojarska-Junak A, Domanski D, Rolinski J, Hus M, Soroka-Wojtaszko M. Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma. Leuk Lymphoma 2002; 43: 401-406.
25. Laurenti L, Piccioni P, Tarnani M, De Padua L, Garzia M, Efremov DG et al. Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pre-treated patients with chronic lymphocytic leukemia. Leuk Res 2007; 31: 253-256.
26. Giannopoulos K, Dmoszynska A, Rolinski J. Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pretreated patients with chronic lymphocytic leukemia. Leuk Res 2007; 31: 411-412.
27. Friedberg JW, Dong DA, Li S, Kim H, Stephans K, Noonan K et al. Oral fludarabine has significant activity in patients with previously untreated chronic lymphocytic leukemia, and leads to increased STAT1 levels in vivo. Leuk Res 2004; 28: 139-147.
28. Gomez-del Arco P, Maki K, Georgopoulos K. Phosphorylation controls Ikaros's ability to negatively regulate the G(1)-S transition. Mol Cell Biol 2004; 24: 2797-2807.
29. Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J et al BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 2008; 453: 110-114.
30. Rosenwald A, Staudt LM. Clinical translation of gene expression profiling in lymphomas and leukemias. Semin Oncol 2002; 29: 258-263.
31. Munzert G, Kirchner D, Stobbe H, Bergmann L, Schmid RM, Dohner H et al. Tumor necrosis factor receptor-associated factor 1 gene overexpression in B-cell chronic lymphocytic leukemia: Analysis of NF-kappa B/Rel-regulated inhibitors of apoptosis. Blood 2002; 100: 3749-3756.
32. Allan LA, Morrice N, Brady S, Magee G, Pathak S, Clarke PR. Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK. Nat Cell Biol 2003; 5: 647-654.
33. Binsky I, Haran M, Starlets D, Gore Y, Lantner F, Harpaz N et al. IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival. Proc Natl Acad Sci USA 2007; 104: 13408-13413.
34. Wierda WG, Johnson MM, Do KA, Manshouri T, Dey A, O'Brien S et al. Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia. Br J Haematol 2003; 120: 452-456.